StreetInsider.com News Articles

ICU Medical Announces Time of Second Quarter 2026 Earnings Conference Call

Thu, 23 Jul 2026 08:30:00 -0400

SAN CLEMENTE, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its second quarter 2026 earnings release and conference call.

The Company will release its second quarter 2026 results on Thursday, August 6, 2026 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Thursday, August 6, 2026. The call can be accessed at 1-800-420-1459, conference ID “ICUMED”. The

ICU Medical Announces Time of Second Quarter 2026 Earnings Conference Call

Thu, 23 Jul 2026 08:30:00 -0400

ICU Medical Announces Time of Second Quarter 2026 Earnings Conference Call

Thu, 23 Jul 2026 08:30:00 -0400

ICU Medical Announces Time of Second Quarter 2026 Earnings Conference Call

Thu, 23 Jul 2026 08:30:00 -0400

ICU Medical (ICUI) PT Raised to $182 at KeyBanc

Tue, 21 Jul 2026 07:44:35 -0400

(Updated - July 21, 2026 7:44 AM EDT)

KeyBanc analyst Brett Fishbin raised the price target on ICU Medical (NASDAQ: ICUI) to $182.00 (from $164.00) while maintaining an Overweight rating.

The analyst commented: "We continue to highlight LIVN, ICUI, and STE as key ideas – and are increasing our PTs for ICUI ($182 from $164) and ITGR ($104 from $99).We believe ICUI remains well positioned, given a steady backdrop for core hospital volumes and anticipate a potential increased contribution from new Infusion Pump placements in 2Q.

We remain encouraged by ICUI’s progress in demonstrating increased operational and financial stability. Specifically, ICUI has progressed

ICU Medical (ICUI) PT Raised to $182 at KeyBanc

Tue, 21 Jul 2026 07:44:35 -0400

(Updated - July 21, 2026 7:44 AM EDT)

KeyBanc analyst Brett Fishbin raised the price target on ICU Medical (NASDAQ: ICUI) to $182.00 (from $164.00) while maintaining an Overweight rating.

We remain encouraged by ICUI’s progress in demonstrating increased operational and financial stability. Specifically, ICUI has progressed

Otsuka ICU Medical plans $500M+ IV plant expansion in Austin

Thu, 09 Jul 2026 08:32:12 -0400

Otsuka ICU Medical LLC announced plans for a more than $500 million expansion of its intravenous solutions manufacturing operations in Austin, Texas, according to a company press release.

The project includes upgrades to the joint venture's existing 700,000-square-foot Austin facility and the construction of a new 500,000-square-foot facility at the same location. The expansion is intended to increase supply resiliency, support non-DEHP product development, and add manufacturing capacity for IV solutions and specialty pharmaceuticals.

Otsuka ICU Medical LLC is a joint venture between ICU Medical, Inc. (NASDAQ: ICUI) and Otsuka Pharmaceutical Factory America, Inc., a subsidiary of Otsuka Pharmaceutical Factory, Inc. The

Otsuka ICU Medical LLC Announces Over $500M Expansion of IV Solutions Manufacturing in North America

Thu, 09 Jul 2026 08:30:00 -0400